The costs and benefits of deprescribing Proton Pump Inhibitors.

Tuinhof, Jesse (2022) The costs and benefits of deprescribing Proton Pump Inhibitors. Research Project, Pharmacy.

Preview	Text mPHAR_2022_TuinhofJ.pdf Download (2MB) | Preview
	Text toestemming.pdf Restricted to Registered users only Download (143kB)

Abstract

The primary objective of this project was to determine the economic impact deprescribing proton pump inhibitors (PPIs) had on the patient population of the Twentse Apothekers Organisatie (TAO-UA). To answer this question a simulation model was made to predict the consequences of long term PPI use, based on the potential adverse events related to the kidney. This model was made with the results obtained from a deprescribing pilot performed by the TAO-UA. Afterwards the model was run with the patient population of individual TAO-UA pharmacies. Furthermore different patient groups were examined with the help of the model to determine which group should be prioritized. For this project people with diabetes, diuretic users and different age groups were specifically looked at. In the end deprescribing was expected to be the dominant strategy for an average TAO-UA pharmacy with on average a cost reduction of €11,363 while also gaining 0.366 QALYs per person. This required an initial investment of around €17.47 per person with the annual follow-up excluded. If not everyone in the population could be deprescribed the younger population should be prioritized.

Item Type:	Thesis (Research Project)
Supervisor name:	Feenstra, T.L.
Degree programme:	Pharmacy
Thesis type:	Research Project
Language:	English
Date Deposited:	30 Mar 2022 09:37
Last Modified:	30 Mar 2022 09:37
URI:	https://fse.studenttheses.ub.rug.nl/id/eprint/26794

Actions (login required)

View Item